# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 03-13-2024 | 12-31-2023 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.56...
ADC Therapeutics SA (NYSE:ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluat...
HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $9 price target.
Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy.
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical tr...
Guggenheim analyst Michael Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Buy rating and announces Price ...
RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.